{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-030262","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.767482+00:00","generated_at":"2026-06-13T22:28:48.479713+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bionano shareholders approve reverse split authorization; directors elected","bullets":["Stockholders approved a reverse stock split at a ratio between 1-for-5 and 1-for-10 at board's discretion.","Proposal 4: 2.064B votes for, 1.077B against, 0.936M abstain (including Series A Preferred votes).","Elected Class II directors: Albert Luderer, Kristiina Vuori, Hannah Mamuszka for three-year terms.","Advisory vote on executive compensation passed with 28.96M for, 25.69M against.","Ratified BDO USA as independent auditor for FY2023 with 123.52M for."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-030262","json":"https://secwatch.observer/filing/0001140361-23-030262.json","markdown":"https://secwatch.observer/filing/0001140361-23-030262.md","text":"https://secwatch.observer/filing/0001140361-23-030262.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123030262/0001140361-23-030262-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123030262/brhc20054531_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:28:48.479713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ec66b951a2f0d70659ed63a201aa4a538ce0c78","claim":"Bionano Genomics, Inc. shareholders approved Approval of a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-10 at the 2023-06-14 meeting.","evidence_excerpt":"The Company’s stockholders approved a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect, at the option of the Company’s Board of Directors, a reverse stock split of the Company’s common stock at a ratio between 1-for-5 and 1-for-10, inclusive, as determined by the Company’s Board of Directors in its sole discretion.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123030262/0001140361-23-030262-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"1e5264e7c9cd49d4b61230f75e51676f6cab4e71","claim":"Bionano Genomics, Inc. shareholders approved Election of Class II Directors at the 2023-06-14 meeting.","evidence_excerpt":"The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123030262/0001140361-23-030262-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"4e5cec35e3ebad44ee1cc93eee64858a42fca8bd","claim":"Bionano Genomics, Inc. shareholders approved Advisory approval of the compensation of the Company’s named executive officers at the 2023-06-14 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement relating to the Annual Meeting.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123030262/0001140361-23-030262-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"5a768866a6a8b4316547d26b2b078dffc4bd0df8","claim":"Bionano Genomics, Inc. shareholders approved Authorization to adjourn the Annual Meeting to solicit additional proxies if necessary at the 2023-06-14 meeting.","evidence_excerpt":"The Company’s stockholders approved the authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes in favor of Proposal 4.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123030262/0001140361-23-030262-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"},{"claim_id":"73845f009d1ed25f49603838fef4fdaaec042279","claim":"Bionano Genomics, Inc. shareholders approved Ratification of the selection of BDO USA, LLP as independent registered public accounting firm at the 2023-06-14 meeting.","evidence_excerpt":"The Company’s stockholders ratified the selection of BDO USA, LLP by the Audit Committee of the Board as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036123030262/0001140361-23-030262-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}